TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19186342
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (scaling and root planing without GM gel application)
Study: 8839551
Drug: LHRH agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHRH agonist triptorelin (3.75 mg monthly injections)
Study: 30200281
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A therapy (BoNT‐A) combined with intensive rehabilitation (IR)
Study: 24243216
Drug: Oxycodone powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone powder (Oxy API) 30mg
Study: 19394603
Drug: Intraoperative multimodal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative multimodal analgesia (Diclofenac sodium 100 mg suppository and 0.75% Ropivacaine)
Study: 17825128
Drug: Monthly bisphosphonate
Normalized name: methylene diphosphonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly bisphosphonate therapy
Study: 17825128
Drug: Weekly bisphosphonate
Normalized name: methylene diphosphonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly bisphosphonate therapy
Study: 9952362
Drug: Zidovudine combined
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine combined with HIV hyperimmune immunoglobulin (HIVIG) infusions administered monthly during pregnancy and to the neonate at birth
Study: 9952362
Drug: Zidovudine and
Normalized name: zidovudine and lamivudine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine and intravenous immunoglobulin (IVIG) without HIV antibody
Study: 2407030
Drug: Long-acting nifedipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting nifedipine (mean daily dose, 52 mg in 2 divided doses)
Study: 2407030
Drug: Metoprolol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (mean daily dose, 155 mg in 2 divided doses)
Study: 20855672
Drug: Long-pulsed 1064-nm
Normalized name: LONG PEPPER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-pulsed 1064-nm Nd:YAG laser treatment
Study: 20017331
Drug: TMZ capsule
Normalized name: TMZ
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TMZ capsule 150 mg/m2 orally on days 1-5 and CCNU placebo 130 mg/m2 on day 1
Study: 20017331
Drug: CCNU capsule
Normalized name: Lomustine
DrugBank: Lomustine (DB01206)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CCNU capsule 130 mg/m2 orally on day 1 and TMZ placebo 150 mg/m2 on days 1-5
Study: 16696391
Drug: Preoperative '3-in-1'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative '3-in-1' Femoral Nerve Block (FNB) using 30 mL of bupivacaine 0.25%
Study: 16696391
Drug: Postoperative '3-in-1'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative '3-in-1' Femoral Nerve Block (FNB) using 30 mL of bupivacaine 0.25%
Study: 3436330
Drug: Iopamidol (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iopamidol (1.5 ml kg‐1)
Study: 3436330
Drug: Amidotrizoate (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amidotrizoate (1.5 ml kg‐1)
Study: 3436330
Drug: Amidotrizoate (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amidotrizoate (40 ml)
Study: 3436330
Drug: Iopamidol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iopamidol (40 ml)
Study: 23228561
Drug: Risedronate sodium
Normalized name: Risedronate Sodium
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Risedronate sodium (35 mg/wk) for 4 months
Study: 12585724
Drug: L-carnosine (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnosine (800 mg daily for 8 weeks)
Study: 31306076
Drug: Rapid maxillary
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid maxillary expansion (RME) treatment
Study: 31306076
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (sham appliance)
Study: 30552531
Drug: Mastery Enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mastery Enhancement Therapy
Study: 30378151
Drug: L-NMMA (n=13)
Normalized name: L-NMMA
DrugBank: Tilarginine (DB11815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA (n=13)
Study: 25932544
Drug: Lacosamide 800
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lacosamide 800 mg/day
Study: 25666151
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg/day
Study: 19506391
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment (1.3, 2.0, and 2.7 mg/m²/day)
Study: 15375809
Drug: Heat wrap
Normalized name: Softheat Ultra Back Heat Wrap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat wrap therapy
Study: 9408426
Drug: Heparin-coated 7-FR
Normalized name: Heparine
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin-coated 7-FR femoral venous catheters
Study: 8208641
Drug: Lisinopril 10‐40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 10‐40 mg once daily
Study: 8208641
Drug: Nifedipine 20‐40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 20‐40 mg twice daily
Study: 3114434
Drug: CP (cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP (cyclophosphamide and cisplatin both administered intravenously on a single day at 3‐week intervals)
Study: 24934484
Drug: Cilostazol (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol (up to 200 mg/day)
Study: 19105351
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine treatment for flat warts, 5 g pre-pack, treated for 30 days.
Study: 19105351
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine treatment for flat warts (control group).
Study: 16632814
Drug: tropisetron (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: tropisetron (0.1 mg/kg)
Study: 2205961
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg zinc sulphate as a depot tablet = 22 mg Zn++ (Zinclet), taken thrice daily for eight weeks
Study: 2205961
Drug: Placebo, taken
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, taken thrice daily for eight weeks
Study: 2205961
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg zinc sulphate as a depot tablet = 22 mg Zn++ (Zinclet)
Study: 626821
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hepatic artery ligation and portal vein perfusion
Study: 31399448
Drug: Glutathione (GSH)
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutathione (GSH) infusion (2500 mg/25 mL over 10 min, followed by the same doses at 24, 48, and 72 hours)
Study: 25348807
Drug: Subcutaneous infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous infiltration of both wound edges with 20 ml of 0.75% ropivacaine
Study: 23480028
Drug: Fentanyl (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (5 μg/kg) intravenously alone
Study: 23480028
Drug: Fentanyl (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (5 μg/kg) intravenously with rifampicin (600 mg single oral dose)
Study: 22153009
Drug: tirofiban +
Approvals — FDA: no, EMA: no, PMDA: no
Description: tirofiban + aspirin and clopidogrel
Study: 19786678
Drug: Dihydropyridine calcium
Normalized name: 4-(2'-Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsäuredimethylester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydropyridine calcium channel blocker (CCB)
Study: 19786678
Drug: GFR between
Normalized name: CYCLIZED P12 (PEPTIDE BOND BETWEEN THE CARBOXY AND AMINO-TERMINAL ENDS OF THE LINEAR PEPTIDE PSHISKYILRWRPK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFR between 31 and 40 mL/min/1.73 m²
Study: 19786678
Drug: GFR <
Normalized name: Glomerular Filtration Rate
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFR < 30 mL/min/1.73 m²
Study: 19786678
Drug: GFR 41
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFR 41 to 50 mL/min/1.73 m²
Study: 16941613
Drug: Cromolyn sodium
Normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cromolyn sodium nasal spray
Study: 16941613
Drug: Cromolyn sodium
Normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cromolyn sodium nasal spray and hydroxyurea capsule
Study: 16941613
Drug: Hydroxyurea capsule
Normalized name: Hydroxyurea Capsules
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea capsule and placebo nasal spray
Study: 7709462
Drug: Lisinopril (LIS,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (LIS, 10‐20 mg o.d.)
Study: 7709462
Drug: Nitrendipine (NIT,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (NIT, 10‐20 mg b.i.d.)
Study: 30056216
Drug: acebilustat 50
Normalized name: Acebilustat
DrugBank: Acebilustat (DB15385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: acebilustat 50 mg
Study: 30056216
Drug: acebilustat 100
Normalized name: Acebilustat
DrugBank: Acebilustat (DB15385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: acebilustat 100 mg
Study: 27362705
Drug: Traditional oral
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional oral medication (Group-I, control)
Study: 20966373
Drug: Culturally sensitive
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally sensitive collaborative treatment (CSCT)
Study: 19132271
Drug: Predictive equation
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Predictive equation I: W(kg) = 0.5030 (AC) + 0.5634 (AbC) + 1.3180 (CC) + 0.0339 (SSSF) - 43.1560
Study: 19132271
Drug: Predictive equation
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Predictive equation II: W(kg) = 0.4808 (AC) + 0.5646 (AbC) + 1.3160 (CC) - 42.2450
Study: 19132271
Drug: Predictive equation
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Predictive equation III: W(kg) = 0.5759 (AC) + 0.5263 (AbC) + 1.2452 (CC) - 4.8689 (S) - 32.9241
Study: 15845683
Drug: Fluvoxamine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (100 mg daily)
Study: 15845683
Drug: Fluvoxamine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (100 mg daily) and Erythromycin (1500 mg)
Study: 12960646
Drug: Inactivated HAV
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated HAV vaccine (Havrix), 720 Elisa units per 0.5 ml dose, administered at months 0 and 6
Study: 6970272
Drug: Rifampin prophylaxis
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin prophylaxis (20 mg/kg once daily for four days)
Study: 22010250
Drug: PHL-NP122 (10^6
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHL-NP122 (10^6 spores/g of feed)
Study: 22010250
Drug: PHL-MM65 (10^6
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHL-MM65 (10^6 spores/g of feed)
Study: 19321970
Drug: Comparator (antidepressant)
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator (antidepressant)
Study: 17446205
Drug: alpha-lactalbumin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-lactalbumin (40 g)
Study: 27435836
Drug: Dexmedetomidine (Dex)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (Dex) intravenous infusion (0.24 to 0.6 μg/kg/h) for <24 hours postoperatively
Study: 22446609
Drug: Four cycles
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four cycles of ABVD followed by 30 Gy of involved-field radiation therapy
Study: 22446609
Drug: Two cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two cycles of ABVD followed by 20 Gy of involved-field radiation therapy
Study: 22446609
Drug: 30 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 Gy of involved-field radiation therapy
Study: 22446609
Drug: 20 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 Gy of involved-field radiation therapy
Study: 19552060
Drug: Antihypertensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive therapy for 3 months
Study: 19552060
Drug: Control subjects
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control subjects (no antihypertensive therapy)
Study: 12883138
Drug: Serotonin reuptake
Normalized name: Selective serotonin reuptake inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotonin reuptake inhibitors (SRIs) including clomipramine, fluvoxamine, fluoxetine, sertraline, and paroxetine
Study: 12883138
Drug: Switching, augmentation,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching, augmentation, or novel-agent strategies for patients who do not respond to SRIs
Study: 11021272
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment consisting of ACE inhibitors (91% of patients), ACE inhibitor dosage (52% of recommended dose), β‐blockers (42%), diuretics (70%), digitalis (63%)
Study: 2336056
Drug: Solution A
Normalized name: I.V. SOLUTION ADDITIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution A (sucrose and maltodextrin)
Study: 2336056
Drug: Solution B
Normalized name: DONISLECEL-JUJN RINSE SOLUTION BAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution B (glucose)
Study: 6986133
Drug: Diazepam (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (15 to 25 mg/day)
Study: 22924169
Drug: Dexamethasone 0.30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.30 mg/kg
Study: 16244842
Drug: 0.8% isoflurane
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8% isoflurane with 2 mg/kg succinylcholine
Study: 16244842
Drug: 1.4% isoflurane
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.4% isoflurane with 2 mg/kg succinylcholine
Study: 9472058
Drug: Iodixanol 270
Normalized name: IODIXANOL 270mgI/ml INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodixanol 270 mgI/ml
Study: 9472058
Drug: Iohexol 300
Normalized name: IOHEXOL 300MG/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iohexol 300 mgI/ml
Study: 2468975
Drug: Diltiazem (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (90 mg every 6 h for up to 14 days)
Study: 1123173
Drug: Metiamide (histamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metiamide (histamine H2-receptor antagonist)
Study: 935972
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Metiamide and Propantheline
Study: 6987023
Drug: Hydrochlorothiazide 100
Normalized name: hydrochlorothiazide 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 100 mg
Study: 29339109
Drug: Bitter gourd
Normalized name: BITTER MELON
DrugBank: Momordica charantia fruit (DB14265)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bitter gourd (2.5g powder daily)
Study: 26651352
Drug: Cognitive-behavioral conjoint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral conjoint therapy for PTSD (CBCT for PTSD)
Study: 24684245
Drug: Thyroid hormone
Normalized name: Thyroid hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid hormone (thyroxine, T4) supplementation at doses of 4, 8, and 16 μg/(kg · day), bolus or continuous administration
Study: 15848674
Drug: tacrolimus+steroids+MMF (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: tacrolimus+steroids+MMF (control arm)
Study: 1978468
Drug: Remoxipride (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remoxipride (mean daily dose: 363 mg)
Study: 1978468
Drug: Haloperidol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (mean daily dose: 9 mg)
Study: 18253955
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal (AC) at a dose of 250 mg three times daily during irinotecan administration
Study: 12839320
Drug: Child Health
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child Health Questionnaire (CHQ‐PF28) administered at 14 days after ED visit
Study: 10919300
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg morphine intraarticularly
Study: 10919300
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg morphine intraarticularly
Study: 10919300
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg saline intraarticularly and morphine intravenously
Study: 1488460
Drug: Behavioral family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral family treatment
Study: 1488460
Drug: Supportive family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive family treatment
Study: 2951818
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide + fenoterol (1 puff per 10 kg body weight, max 4 puffs; each puff contains 0.02 mg ipratropium bromide and 0.05 mg fenoterol)
Study: 27753676
Drug: Z-track technique
Normalized name: Z-160
DrugBank: Z-160 (DB12743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Z-track technique for intramuscular injection
Study: 27753676
Drug: Standard technique
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard technique of intramuscular injection
Study: 25002101
Drug: Jian-Wei-Qu-Tong Pills
Normalized name: beef tongue preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jian-Wei-Qu-Tong Pills (JWQTP) high-dose group
Study: 25002101
Drug: Jian-Wei-Qu-Tong Pills
Normalized name: beef tongue preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jian-Wei-Qu-Tong Pills (JWQTP) low-dose group
Study: 15902961
Drug: Humanized anti-IL-6R
Normalized name: humanized SMART Anti-IL-12 Antibody
DrugBank: humanized SMART Anti-IL-12 Antibody (DB05848)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humanized anti-IL-6R monoclonal antibody (MRA), administered every 2 weeks for 12 weeks
Study: 15902961
Drug: Single MRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single MRA infusion
Study: 31039172
Drug: Aerosol-intradermal vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosol-intradermal vaccination (Group 1)
Study: 31039172
Drug: Intradermal-aerosol vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal-aerosol vaccination (Group 2)
Study: 31039172
Drug: Intradermal-intradermal vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal-intradermal vaccination (Group 3)
Study: 17066402
Drug: Bayesian evaluation
Normalized name: Babesia microti preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bayesian evaluation of group sequential clinical trial designs
Study: 8550254
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g of artificially 13C‐labelled glucose dissolved in 400 ml of water
Study: 19793150
Drug: Barrier-strengthening moisturizing
Normalized name: Soothe & Cool Moisture Barrier
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barrier-strengthening moisturizing cream as maintenance therapy
Study: 19793150
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment after initial steroid course
Study: 16145305
Drug: Medroxyprogesterone acetate,
Normalized name: medroxyprogesterone acetate, micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate, 10 mg/day
Study: 16145305
Drug: Nomegestrol acetate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nomegestrol acetate, 5 mg/day
Study: 16145305
Drug: Dydrogesterone, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dydrogesterone, 10 mg/day
Study: 16145305
Drug: Micronized progesterone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized progesterone, 200 mg/day
Study: 9486936
Drug: Lisinopril alone
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril alone (monotherapy)
Study: 9486936
Drug: Lisinopril with
Normalized name: LISINOPRIL 20 mg / HYDROCHLOROTHIAZIDE 25 mg ORAL TABLET [Lisinopril with Hydrochlorothiazide]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril with trichlormethiazide (combination therapy)
Study: 3315173
Drug: Pseudomonas vaccine
Normalized name: Pseudomonas aeruginosa
DrugBank: Pseudomonas aeruginosa (DB19284)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudomonas vaccine immunotherapy
Study: 3315173
Drug: Tamoxifen with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen with FAC chemotherapy
Study: 14698135
Drug: FAC chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAC chemotherapy
Study: 26481811
Drug: Selenium supplementation
Normalized name: Selenium supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplementation (60 μg/d)
Study: 25395311
Drug: IBUNa 2
Normalized name: OCTINOXATE 2010 mg in 30 mL / OCTOCRYLENE 900 mg in 30 mL / TITANIUM DIOXIDE 600 mg in 30 mL TOPICAL EMULSION [SHISEIDO SYNCHRO SKIN SELF-REFRESHING TINT 215 Light Buna]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBUNa 2 × 256 mg
Study: 22526014
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg administered intravenously prior to surgery
Study: 19017409
Drug: Norepinephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine infusion (n = 16)
Study: 19017409
Drug: Phenylephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine infusion (n = 16)
Study: 16895622
Drug: Doxapram 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxapram 1 mg kg(‐1)
Study: 16895622
Drug: Aminophylline 2
Normalized name: aminophylline 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline 2 mg kg(‐1)
Study: 16895622
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo intravenous
Study: 1607083
Drug: Supplemental oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental oxygen via oral route (2 liters/min)
Study: 7964858
Drug: IVIg treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIg treatment
Study: 30307129
Drug: 4-mm implants
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-mm implants